These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19731394)

  • 21. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
    Fayette J; Fontaine-Delaruelle C; Ambrun A; Daveau C; Poupart M; Ramade A; Zrounba P; Neidhardt EM; Péron J; Diallo A; Céruse P
    Oncotarget; 2016 Jun; 7(24):37297-37304. PubMed ID: 27119503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy for head and neck cancer: recent data.
    Vokes EE
    Oncologist; 2010; 15 Suppl 3():3-7. PubMed ID: 21036882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
    Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
    Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
    Pignon JP; Syz N; Posner M; Olivares R; Le Lann L; Yver A; Dunant A; Lewin F; Dalley DN; Paccagnella A; Taylor SG; Domenge C; Bourhis J; Mazumdar M
    Anticancer Drugs; 2004 Apr; 15(4):331-40. PubMed ID: 15057136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
    Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel in the management of patients with head and neck squamous cell carcinoma.
    Bernier J; Vrieling C
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
    Haddad R; Tishler RB; Norris CM; Mahadevan A; Busse P; Wirth L; Goguen LA; Sullivan CA; Costello R; Case MA; Posner MR
    Oncologist; 2003; 8(1):35-44. PubMed ID: 12604730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
    Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
    Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TPF sequential therapy: when and for whom?
    Budach V
    Oncologist; 2010; 15 Suppl 3():13-8. PubMed ID: 21036884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study.
    Sun Y; Guo W; Bai Y; Ge M; Hu C; Wu S; Hao J; Gao M; Pan J; Dong P; Wu Y; Liang H; Wei Q; Zhong M; Lu T
    Oral Dis; 2020 Mar; 26(2):285-294. PubMed ID: 31830347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
    Fonseca E; Grau JJ; Sastre J; García-Gómez JM; Rueda A; Pastor M; Lara MA; Navalón M; Berrocal A; Tisaire JL; Cruz JJ
    Eur J Cancer; 2005 Jun; 41(9):1254-60. PubMed ID: 15908196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel in squamous cell cancer of the head and neck.
    Posner MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S21-4. PubMed ID: 11340900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current concepts for the management of head and neck cancer: chemotherapy.
    Specenier PM; Vermorken JB
    Oral Oncol; 2009; 45(4-5):409-15. PubMed ID: 18715812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of taxanes and targeted therapies in locally advanced head and neck cancer.
    Specenier P; Vermorken JB
    Curr Opin Oncol; 2007 May; 19(3):195-201. PubMed ID: 17414636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
    J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.